Welcome to our dedicated page for Armata Pharmaceuticals news (Ticker: ARMP), a resource for investors and traders seeking the latest updates and insights on Armata Pharmaceuticals stock.
Armata Pharmaceuticals, Inc. (NYSE American: ARMP) is a clinical-stage biotechnology company dedicated to developing pathogen-specific bacteriophage therapeutics to address antibiotic-resistant and challenging bacterial infections. Utilizing proprietary bacteriophage-based technology, Armata is advancing a broad pipeline of both natural and synthetic phage candidates targeting critical pathogens such as Pseudomonas aeruginosa and Staphylococcus aureus.
Armata's innovative approach includes developing clinical candidates like AP-PA02 and AP-SA02. AP-PA02, a five-phage cocktail, is aimed at treating Pseudomonas aeruginosa infections, particularly in people with cystic fibrosis. The company is currently analyzing data from its SWARM-P.a. study to progress into a Phase 2b/3 registrational study in 2024. Meanwhile, AP-SA02, designed to combat Staphylococcus aureus bacteremia, has shown positive results in Phase 1b trials and is moving into Phase 2a with support from the U.S. Department of Defense.
In collaboration with Merck, Armata is developing proprietary synthetic phage candidates to address other significant infectious diseases. The company’s commitment to innovation extends to its in-house phage-specific GMP manufacturing capabilities, ensuring high-quality production from bench to clinic.
Financially, Armata reported grant revenue of $1.0 million for the second quarter of 2023, attributed to its AP-SA02 program. The company's research and development expenses were approximately $8.3 million, reflecting ongoing investments in clinical trials and personnel. As of June 30, 2023, Armata held $12.5 million in unrestricted cash and cash equivalents, with a subsequent $25 million credit agreement with Innoviva bolstering its financial position.
Recent updates include the initiation of the Phase 2a portion of the diSArm study for AP-SA02 and the positive topline data from the SWARM-P.a. clinical trial. Armata is poised for significant advancements, supported by its strategic partnerships and robust development pipeline.
Armata Pharmaceuticals (NYSE American: ARMP) announced receiving a $3.0 million equity investment from the Cystic Fibrosis Foundation, with an additional $4.0 million from Innoviva, a significant shareholder. This investment will support Armata's lead clinical candidate, AP-PA02, currently in a Phase 1b/2a trial for chronic Pseudomonas aeruginosa infections in cystic fibrosis patients. This follows a prior $5.0 million Therapeutics Development Award from the Foundation in March 2020, emphasizing the urgent need for new therapies against difficult bacterial infections.
Armata Pharmaceuticals, Inc. (NYSE American: ARMP) will participate in the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021. The presentation will be available on-demand starting at 7:00 AM ET on September 13. Armata focuses on developing bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections. Their pipeline includes candidates for pathogens like Pseudomonas aeruginosa and Staphylococcus aureus, and they collaborate with Merck on synthetic phage candidates targeting an undisclosed infectious disease.
Armata Pharmaceuticals (ARMP) reported its second-quarter 2021 results, noting the retirement of CEO Todd R. Patrick and the appointment of Brian Varnum as his successor. The company received a $750,000 milestone payment from the Cystic Fibrosis Foundation to support its Phase 1b/2a clinical trial for AP-PA02 targeting chronic Pseudomonas aeruginosa infections. Grant revenue was $1.2 million, a significant increase from $31,000 in Q2 2020. However, R&D expenses surged to $5.2 million, contributing to an operating loss of $6.2 million. Armata has $17.5 million in cash as of June 30, 2021.
Armata Pharmaceuticals, Inc. (NYSE American: ARMP) announced on August 2, 2021, that CEO Todd R. Patrick is retiring from day-to-day management, transitioning to the Board of Directors as a special advisor. President Brian Varnum, Ph.D., has been appointed CEO. Patrick highlighted the company's significant progress, including the merger with AmpliPhi Biosciences and clinical trials for AP-PA02. The Board expressed gratitude for Patrick's leadership and confidence in Varnum's drug development experience as the company advances phage-based therapeutics targeting antibiotic-resistant infections.
Armata Pharmaceuticals (NYSE American: ARMP), a biotechnology firm focused on bacteriophage therapeutics for antibiotic-resistant infections, will present at the Ladenburg Thalmann 2021 Healthcare Conference on July 13, 2021, at 4:00 PM ET. The event will feature one-on-one investor meetings and further details about Armata's innovative pipeline targeting pathogens such as Pseudomonas aeruginosa and Staphylococcus aureus. Interested parties can access the presentation through a provided webcast link.
Armata Pharmaceuticals, Inc. (ARMP) reported first quarter 2021 results, highlighting progress in clinical trials and financial developments. The company is advancing its SWARM-P.a. Phase 1b/2a trial for treating cystic fibrosis and preparing for a Phase 1b/2 trial for Staphylococcus aureus bacteremia. Armata raised $20 million in gross proceeds from Innoviva, enhancing its financial position, which now includes $22.5 million in cash. The company recognized $1.1 million in grant revenue and expects to achieve several milestones in 2021 and 2022.
Armata Pharmaceuticals, Inc. (NYSE American: ARMP) announced its Q4 and full-year 2020 results, signaling progress in its clinical programs. The FDA cleared the IND application for its lead candidate AP-PA02, aimed at treating Pseudomonas aeruginosa infections. The company appointed Robin C. Kramer to its Board and Mina Pastagia as VP of Clinical Development. Financially, Armata reported Q4 revenues of $0.5 million and a loss from operations of $6.5 million. After raising $20 million from Innoviva, the company has approximately $9.7 million in cash, sufficient to fund operations into Q1 2022.
Armata Pharmaceuticals, Inc. (NYSE American: ARMP) has successfully closed the second and final tranche of a $20 million private placement with Innoviva, Inc. (NASDAQ: INVA). This transaction raised approximately $13.9 million through the issuance of 4,285,935 common shares and warrants at $3.25 each, following a notable 99% shareholder approval. The first tranche, completed on January 26, 2021, raised $6.1 million. Following both closings, Armata now has 24,940,442 shares outstanding and warrants for 16,649,465 additional shares.
Armata Pharmaceuticals (NYSE American: ARMP) announces participation in the Oppenheimer 31st Annual Healthcare Conference from March 16-18, 2021. Management will present on March 17 at 3:10pm ET. The company focuses on bacteriophage therapeutics targeting antibiotic-resistant bacterial infections, with a diverse pipeline including candidates for Pseudomonas aeruginosa and Staphylococcus aureus. Armata collaborates with Merck to develop synthetic phage candidates for an undisclosed infectious disease.
Armata Pharmaceuticals (NYSE American: ARMP) announced a securities purchase agreement with Innoviva (Nasdaq: INVA), securing approximately $20 million in gross proceeds. The funds will support Armata's bacteriophage development programs, including the FDA-cleared SWARM-P.a. study for AP-PA02 targeting Pseudomonas aeruginosa infections. The agreement includes the purchase of 6.2 million shares at $3.25 each and warrants, scheduled in two tranches. Armata aims to achieve significant clinical milestones in 2021 and 2022, advancing its pipeline for combatting antibiotic-resistant infections.
FAQ
What is the current stock price of Armata Pharmaceuticals (ARMP)?
What is the market cap of Armata Pharmaceuticals (ARMP)?
What does Armata Pharmaceuticals specialize in?
What are Armata's lead clinical candidates?
Who are Armata's key collaborators?
What are the recent financial highlights for Armata?
What recent developments have been announced by Armata?
In which clinical stage is Armata's AP-PA02 candidate?
What is the significance of Armata's in-house GMP manufacturing?
How does Armata plan to address antibiotic-resistant infections?
What is the role of Merck in Armata's development programs?
What grants and financial support has Armata received?
